New pill raises hopes for low platelet disorder

NCT ID NCT07196163

Not yet recruiting Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests golidocitinib, an oral drug, in adults with immune thrombocytopenia (ITP) whose platelet counts remain low despite prior treatments. The study has two parts: first, finding a safe dose, then comparing the drug against a placebo in a blinded fashion. The main goal is to see if the drug can safely raise and maintain platelet counts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: golidocitinib
What this could lead to: If it works, this could point toward a new oral treatment option for people with immune thrombocytopenia who have not responded to standard therapies.
What could go wrong: This is an early phase 1/2 trial with a small number of participants, so safety and effectiveness are not yet proven. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE THROMBOCYTOPENIA (ITP)

Contacts and locations

Locations

Peking University Insititute of Hematology, Peking University People's Hospital

Beijing, Beijing Municipality, 100010, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.